Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Aska Pharmaceuticals Of Japan Enhances Pipeline And Plans To Enter Generics Market

This article was originally published in PharmAsia News

Executive Summary

Aska Pharmaceuticals President Takashi Yamaguchi expects menopausal symptoms drug Menoaid Patch will be NHI price-listed within the year. With an estimated ¥2 billion in potential sales, Aska will establish a team to prepare for next year's market launch. Aska has eight items in its pipeline, including Tavocept (dimensa), a neuropathy drug to reduce side effects of taking cancer drugs, that has shown promising results in Phase III trials in Japan. Yamaguchi also disclosed that the company plans to enter generics field with a focus on internal medicine, urology, OBGYN and otology drugs, Aska sets a ¥10 billion sales goal by fiscal year 2010. (Click here for more - Japanese language

You may also be interested in...

Ironwood Ends Phase III GERD Program, Will Cut 100 Jobs

The company has no development programs left in its R&D pipeline and will focus entirely on the commercialization of IBS drug Linzess while seeking late-stage assets from external sources.

FDA Finalizes Guidance On Blood Glucose Meters With Separate Documents For OTC, Rx Devices

The documents issued by the US agency on 29 September set slightly different accuracy standards, reflecting the increased fragility of hospital patients.

Hahn Praises CDRH Staff For Mitigating COVID-19 Deaths

The US FDA commissioner published a blog post commending and highlighting the work device center staff have done during the pandemic to speed tests and devices to market to save lives.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts